Skip to content

A Clinical Trial to Evaluate the Effect of ConcenTrace Trace Mineral Drops on Gut Health

A Clinical Trial to Evaluate the Effect of ConcenTrace Trace Mineral Drops on Gut Health

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06122571
Enrollment
40
Registered
2023-11-08
Start date
2023-10-05
Completion date
2024-01-31
Last updated
2024-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloating, Bowel Movements, Constipation, Gut Health

Brief summary

This is a virtual single-arm trial that will last 12 weeks. Participants will take the drops daily and complete questionnaires at Baseline, Week 4, Week 8, and Week 12. Gut health, bowel movements, stool looseness, constipation, bloating, and regularity will be evaluated at the Baseline and at each check-in. Likert scale responses will be statistically compared from Baseline to each check-in. Participant responses and product feedback will be presented as percentage scores.

Interventions

The product contains concentrated seawater from Utah's inland sea.

Sponsors

Citruslabs
CollaboratorINDUSTRY
Trace Minerals
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Be male or female. Be aged over 18. Have a BMI less than 35. Have issues with digestion, heartburn, indigestion, gas, or constipation. Be willing to maintain their standard dietary pattern, activity level, and body weight for the duration of the study. Be generally healthy - must not live with any uncontrolled disease.

Exclusion criteria

* Any person with a pre-existing chronic condition that might prevent the participant from adhering to the protocol, including any oncological and psychiatric disorders. Anyone taking any prescribed medication targeting the gut. Anyone taking any supplements targeting the gut within the past month. Anyone with any known severe allergic reactions. Women who are pregnant, breastfeeding, or attempting to become pregnant. Anyone unwilling to follow the study protocol.

Design outcomes

Primary

MeasureTime frameDescription
Changes in scores on the Gastrointestinal Symptom Rating Scale (GSRS). [Timeframe: Baseline to Week 12]12 weeksThe GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.

Secondary

MeasureTime frameDescription
Changes in stool consistency reported via the Bristol Stool Chart. [Timeframe: Baseline to Week 12]12 weeksThe Bristol stool scale is a diagnostic medical tool designed to classify the form of human faeces into seven categories. Type 1 has spent the longest time in the bowel and type 7 the least time.
Changes in bowel movement frequency. [Timeframe: Baseline to Week 12]12 weeksThe frequency that the participants have a bowel movement will be recorded via questionnaires.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026